{"entity":{"id":"nct04851613","kind":"trial","name":"Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer","aka":[],"tldr":"A phase 3 trial of Afuresertib in advanced solid tumours, run by Laekna Limited, active and no longer recruiting.","summary":"Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer is a phase 3 interventional study registered as NCT04851613 by Laekna Limited, with 256 participants enrolled, started 2022-02-18 and due to reach its primary completion in 2026-10-30. Interventions recorded: Afuresertib and Afuresertib/placebo.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04851613","url":"https://clinicaltrials.gov/study/NCT04851613"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["endocrine-therapy"],"targets":[],"drugs":["fulvestrant"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04851613","phase":"3","setting":"A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies","sponsor":"Laekna Limited","started":"2022-02-18","startedType":"actual","enrolled":256,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04851613/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"drug":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"}]}}